The Effect of High Intensity Interval Training on Cardiovascular Fitness in People With Progressive Multiple Sclerosis.
- Conditions
- Multiple Sclerosis, Progressive
- Interventions
- Other: Continuous moderate exerciseOther: High intensity interval training
- Registration Number
- NCT02950454
- Lead Sponsor
- University of Glasgow
- Brief Summary
This is a pilot trial to explore the cardiovascular of eight weeks of twice weekly high intensity interval training in people with progressive multiple sclerosis. A control group of people with progressive multiple sclerosis will undergo continuous moderate intensity exercise, twice weekly for 8 weeks.
- Detailed Description
This is a pilot trial to explore the cardiovascular of eight weeks of twice weekly high intensity interval training in people with progressive multiple sclerosis. A control group of people with progressive multiple sclerosis will undergo continuous moderate intensity exercise, twice weekly for 8 weeks.
The training program will entail 6x1.5 minute intervals working at 80-95% heart rate max on a cycle ergometer. Each interval will be interspersed with 1.5 minutes of working rest at a light resistance of the participant's choosing.
The continuous moderate intensity exercise program will entail 20 minutes on a cycle ergometer working at 60-70% heart rate max.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 12
- Diagnosed with a progressive form of MS
- Aged 18 years or older
- Known to members of staff of the MS service NHS Ayrshire & Arran
- Ability to attend Douglas Grant Rehabilitation centre twice a week for eight weeks
- EDSS 4-6.0
- Able to cycle on ergometer
- A relapse of symptoms requiring treatment within the past three months.
- A respiratory condition that would be exacerbated by high intensity exercise including but not limited to: chronic obstructive pulmonary disorder, uncontrolled or poorly controlled asthma.
- Uncontrolled high pressure at screening (>190/100 mmHg)
- Cognitive impairment affecting ability to understand instructions as noted in patient's notes.
- Currently engaging in another research trial for their MS or that may affect their physiological or cardiovascular outcomes
- Weighing more than 110 kg (weight limit of ergometer)
- Any pathology or medical intervention that would preclude high intensity exercise, maximal exertion testing or could attenuate the cardiovascular effect of exercise including but not limited to: unstable angina; diabetes; peripheral vascular disease or intermittent claudication; having a pace maker or medicine pump; surgical clips; having another neurological condition other than MS; and pregnancy. To be established from patient's notes and at screening session.
- A serious cardiovascular event in the past year including but not limited to: transient ischaemic attack, cerebrovascular event and myocardial infarction.
- Taking any of the following medication: beta blockers; vasodilators; ACE inhibitors; diuretics or any other medication that could cause exercise induced hypotension; hypoglycaemic insulin; metformin or other oral insulin medicine.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description control Continuous moderate exercise 8 weeks of twice weekly continuous moderate intensity exercise. Session protocol: 2 minutes warm up at nominal resistance on cycle ergometer, 20 minutes at 60-70% heart rate max. Then 3 minutes cool down. Intervention High intensity interval training 8 weeks of twice weekly high intensity interval training. Session protocol: 2 minute warm up at nominal resistance on cycle ergometer, 6 six intervals of 80-95% heart rate max interspersed with 6 intervals of 1.5 minute working rest. Then 3 minutes cool down.
- Primary Outcome Measures
Name Time Method heart rate max 8 weeks Maximal heart rate elicited during a maximal exertion test
- Secondary Outcome Measures
Name Time Method Resting blood pressure 8 weeks Fatigue severity scale 8 weeks Questionnaire which gives measure of fatigue.
Resting heart rate 8 weeks Brain derived neurotrophic factor 8 weeks Hormone important for brain growth and protection
Lactate 8 weeks Waste materials from exercise in blood
Timed 25 foot walk test 8 weeks Measure of walking speed
Symbol digit modalities test 8 weeks Measure of mental processing speed
Lipoprotein profile 8 weeks Indication of how much good and how much bad cholesterol is in blood
MSIS-29 version 2 8 weeks Questionnaire giving physical and psychological impact of MS
Hospital anxiety and depression scale 8 weeks Questionnaire giving a score of depression and anxiety
Trial Locations
- Locations (1)
The University of Glasgow
🇬🇧Glasgow, United Kingdom